Answers are grounded in this paper and cite their sources.
Scientific commentary reveals how NQO1 genotypes alter idebenone response in neuromuscular diseases, highlighting the need to re-evaluate past clinical trials.
Carelli et al. argue that new insights into how NQO1 influences the response to idebenone warrant reevaluating the results of previous clinical trials, including those in Friedreich ataxia and Duchenne muscular dystrophy, using patient stratification by NQO1 genotype.
No takes yet. Share an insight, caveat, or question.
Carelli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: